We regret to report that long term Genuit Group plc (LON:GEN) shareholders have had that ... Investors in Genuit Group had a tough year, with a total loss of 7.1% (including dividends), against ...
We regret to report that long term Genuit Group plc (LON:GEN) shareholders have had that experience ... Investors in Genuit Group had a tough year, with a total loss of 7.1% (including dividends), ...
LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback